Empagliflozin for treating chronic heart failure with reduced ejection fraction

for treating heart failure with empagliflozin. So, it should only be started on advice from a heart failure specialist. 2 Information about empagliflozin Marketing authorisation indication 2.1 Empagliflozin (Jardiance, Boehringer Ingelheim) has a marketing authorisation 'in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction'. Dosage in the marketing authorisation 2.2 The dosage schedule is available in the summary of product characteristics. Price 2.3 The list price of 10 mg or 25 mg empagliflozin is £36.59 per 28-tablet pack (excluding VAT; BNF online, accessed November 2021). The annual treatment cost is £476.98. Costs may vary in different settings because of negotiated procurement discounts. 3 Committee discussion The appraisal committee considered evidence submitted by Boehringer Ingelheim, a review of this submission by the evidence review group (ERG) and responses from stakeholders. See the committee papers for full details of the evidence. The condition People with chronic heart failure with reduced ejection fraction would welcome a new treatment option 3.1 Heart failure with reduced ejection fraction is a chronic condition that affects survival and quality of life. The patient experts highlighted the psychological effects of a diagnosis. They explained that breathlessness, extreme fatigue and fluid accumulation in particular
